Pacific Biosciences Q1 2024 Adj EPS $(0.26) Beats $(0.28) Estimate, Sales $38.810M Miss $42.962M Estimate
Portfolio Pulse from Benzinga Newsdesk
Pacific Biosciences (PACB) reported Q1 2024 adjusted EPS of $(0.26), beating estimates by 7.14% but missed sales estimates with $38.810M versus the expected $42.962M. This represents a slight improvement in losses per share compared to last year but a minor decrease in sales.
May 09, 2024 | 8:08 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Pacific Biosciences reported a smaller than expected loss per share but missed on revenue forecasts for Q1 2024.
The mixed earnings report from Pacific Biosciences, with a better-than-expected EPS but a miss on sales, could lead to uncertain short-term stock movement. Investors might react positively to the reduced losses but could be concerned about the slight sales decline.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100